Anindyojati, Sasongko Prabasworo and dr. Hikmawan Wahyu Sulistomo, Ph.D and dr. Aurick Yudha Nagara, Sp.EM (2023) Hubungan Penggunaan Tocilizumab Dengan Length of Stay dan Kejadian Mortalitas Pada Pasien Covid-19 di RSUD Dr. Saiful Anwar Malang. Sarjana thesis, Universitas Brawijaya.
Abstract
Covid-19 ialah infeksi virus SARS-CoV-2 yang menyebabkan infeksi dalam saluran napas baik ringan maupun parah. Kejadian ini pada awalnya muncul di Wuhan, Cina setelah itu dengan cepat mengalami penyebaran menuju daerah lain. Gejala ISPA ringan hingga berat ataupun hingga acute respiratory distress syndrome (ARDS) dapat disebabkan oleh infeksi Covid-19. Beberapa kejadian mortalitas pasien yang menderita Covid-19 berhubungan dengan badai sitokin. Produksi sitokin proinflamasi yang terlalu tinggi dapat menyebabkan ARDS dan kegagalan organ hingga kematian. Salah satu terapi untuk menghambat badai sitokin adalah Tocilizumab yang berfungsi menghambat reseptor interleukin 6 (IL-6) untuk menahan produksi IL-6 yang eksesif. Penelitian ini memiliki tujuan mengetahui hubungan antara penggunaan tocilizumab dengan length of stay dan kejadian mortalitas terhadap pasien Covid-19 di RSUD Dr. Saiful Anwar Malang. Desain analitik observasional digunakan dalam penelitian ini serta menggunakan data yang diambil dari Rekam Medik RSUD Dr. Saiful Anwar Malang. Data riset studi ini menggunakan retrospektif kohort guna mendapatkan hubungan penggunaan Tocilizumab dengan length of stay dan kejadian mortalitas pasien yang menderita Covid-19 di RSUD Dr. Saiful Anwar Malang yang berperiode Juli hingga September 2021. Berdasarkan data rekam medik ada 14 sampel untuk kelompok pengguna Tocilizumab memenuhi kritera inklusi, serta 28 sampel untuk kelompok kontrol. Hasil penelitian hubungan penggunaan obat Tocilizumab dengan lama rawat inap dan kejadian mortalitas berdasarkan uji Shapiro-Wilk menunjukkan signifikansi p = 0,006. Dilakukan uji Kruskall Wallis mengenai length of stay, didapatkan perbedaan length of stay yang bermakna antara pasien yang mengkonsumsi obat tocilizumab dengan pasien yang tidak mengonsumsi obat tocilizumab, yang bernilai signifikansi p = 0,043 (p<0,05). Dilakukan uji Chi-Square mengenai kejadian mortalitas, tidak ada perubahan signifikan antara penggunaan obat tocilizumab dengan kejadian mortalitas pasien, yang bernilai signifikansi p = 0,172 (P>0,05). Kesimpulan yang bisa ditarik dalam riset ini ialah adanya keterkaitan antara pemakaian Tocilizumab dengan length of stay dan kejadian mortalitas pasien Covid-19 di RSUD Dr. Saiful Anwar Malang. Penggunaan tocilizumab akan menurunkan kejadian mortalitas bagi pasien Covid-19 di RSUD Dr. Saiful Anwar Malang, karena angka kemungkinan hidup lebih panjang maka length of stay pasien yang menggunakan tocilizumab akan meningkat.
English Abstract
Covid-19 infection caused by SARS-CoV-2 virus, result in both mild and severe respiratory infections. This incident began in Wuhan, China, and spread quickly to other cities. Covid-19 infection can cause symptoms ranging from mild to severe ARI to acute respiratory distress syndrome (ARDS). Several fatal events in Covid-19 patients have been linked to cytokine storms. Excessive proinflammatory cytokine production can result in ARDS, organ failure, and even death. Tocilizumab, one of the therapies used to prevent cytokine storms, works by inhibiting interleukin 6 (IL-6) receptors, thereby limiting excessive IL-6 production. The purpose of this study is to learn more about the relationship between the use of tocilizumab and the length of stay as well as the incidence of fatality in Covid-19 patients at Dr. Saiful Anwar Malang. Observational analytic design and data from RSUD Dr. Saiful Anwar Malang's medical records used in this study. This study's research data used a retrospective cohort to determine a relationship between the use of Tocilizumab and the length of stay and the incidence of fatality in Covid-19 patients at RSUD Dr. Saiful Anwar Malang from July to September 2021. 14 samples were obtained from the medical record data for the Tocilizumab user group that met the inclusion criteria, and 28 samples were obtained for the control group. The Shapiro-Wilk test revealed a significance of p = 0.006. The Kruskall Wallis test was performed on length of stay, and a significant difference in length of stay was found between patients who received tocilizumab and patients who did not receive tocilizumab, with a significance value of p = 0.043 (p 0.05). The Chi-Square test was also used to determine the incidence of fatality, and there was no significant difference between the use of tocilizumab and the incidence of patient fatality, with a significance value of p = 0.172 (P> 0.05). Conclusion: There is a relationship between the use of Tocilizumab and length of stay and the incidence of fatality in Covid-19 patients at Dr. Saiful Anwar Malang. Tocilizumab use will reduce the incidence of fatality for Covid-19 patients at Dr. Saiful Anwar Malang; however, because the probability of survival is increased, the length of stay for patients using tocilizumab will increase.
| Item Type: | Thesis (Sarjana) |
|---|---|
| Identification Number: | 0523060165 |
| Uncontrolled Keywords: | Badai Sitokin; Covid-19; Length of Stay; Mortalitas; Tocilizumab |
| Subjects: | 600 Technology (Applied sciences) > 610 Medicine and health |
| Divisions: | Fakultas Kedokteran > Pendidikan Dokter |
| Depositing User: | Endang Susworini |
| Date Deposited: | 18 Dec 2023 02:13 |
| Last Modified: | 18 Dec 2023 02:13 |
| URI: | http://repository.ub.ac.id/id/eprint/205333 |
![[thumbnail of DALAM MASA MEMBARGO]](http://repository.ub.ac.id/style/images/fileicons/text.png) |
Text (DALAM MASA MEMBARGO)
Sasongko Prabasworo Anindyojati.pdf Restricted to Registered users only until 31 December 2025. Download (1MB) |
Actions (login required)
 |
View Item |